Media Summary: Tamim Niazi, MD, McGill University, Montreal, Quebec, Canada, discusses the randomized Phase III PCS5 This video provides a high-yield, visual summary of the Prof Dearnaley talks to ecancertv at ECC 2015 about the results of a phase III
Hypo Flame Trial 5 Year - Detailed Analysis & Overview
Tamim Niazi, MD, McGill University, Montreal, Quebec, Canada, discusses the randomized Phase III PCS5 This video provides a high-yield, visual summary of the Prof Dearnaley talks to ecancertv at ECC 2015 about the results of a phase III Mira Keyes, MD, FRCPC, FABS, British Columbia Cancer Agency, Vancouver, British Columbia, Canada, outlines advancements ... Alison Tree, MBBS, FRCR, MD(res), The Royal Marsden NHS Foundation Trust, London, UK, gives an overview of recent ... Dose-Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Deprivation for Intermediate-Risk Prostate ...
Matteo Carlino, FRACP, PhD, The University of Sydney and Westmead Hospital, Sydney, Australia, presents Evidence from the recent SPARTAN and PROSPER Join us in this insightful episode of the Oncology Brothers podcast as we dive deep into the current treatment landscape of ... For the first time, investor Guy Spier steps outside the world of finance to share a deeply personal conversation—with the doctors ... PCRI's Executive Director, Mark Scholz, MD, discusses the use of clinical Nicholas Blondin, MD, Yale University School of Medicine, New Haven, CT, discusses findings from a Phase I
Neal Shore, MD, Carolina Urologic Research Center, Myrtle Beach, SC, USA, discusses data coming from the HERO phase III ... Donate to PCRI: For more information, visit 0:30 Why is Gleason 8 cancer considered ... Learn more about Dr. Amar Kishan here: To learn more about prostate cancer, ...
